An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.
An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.
复制标题
DOI：
10.1001/jama.2008.803
复制
发表时间：
2008-12-10
影响因子：
120.7
通讯作者：
Burke, Wylie
中科院分区：
文献类型：
--
作者：
McGuire, Amy L.;Burke, Wylie
现在，人们可以了解他们对几十种常见和复杂疾病的遗传易感性，如冠状动脉疾病，糖尿病，肥胖症，前列腺癌和阿尔茨海默病，而无需看医生。直接面向消费者的个人基因组测试公司，如23andMe，Navigenics，和deCODEme希望通过提供量身定制的遗传风险评估，使消费者能够控制自己的健康，评估的基础是报告的基因组变异和疾病易感性之间的联系。几个州限制或禁止这种做法，因为它违反了州法律，该法律要求在提供医疗诊断时，有执照的医生必须适当参与信息（1）。个人基因组测试公司声称他们的服务仅用于信息和教育目的。他们警告消费者，这些信息不应用于诊断，治疗或健康确定目的，如果他们对自己的健康状况有疑问或担忧，请直接咨询医生（2-3）。
It is now possible for individuals to learn about their genetic susceptibility to dozens of common and complex disorders, such as coronary artery disease, diabetes, obesity, prostate cancer, and Alzheimer’s disease, without ever seeing a physician. Direct-to-consumer personal genome testing companies, such as 23andMe, Navigenics, and deCODEme hope to empower consumers to take control of their health by providing tailored assessments of genetic risk based on reported associations between genomic variation and susceptibility to disease.Several states limit or forbid this practice as a violation of state law that requires the appropriate involvement of a licensed physician when providing medical diagnostic information (1). Personal genome testing companies claim that their services are for informational and educational purposes only. They warn consumers that the information should not be used for diagnosis, treatment, or health ascertainment purposes and direct them to their physician if they have questions or concerns about their health status (2–3).
影响因子：
158.5
作者：
HIATT, HH
通讯作者：
HIATT, HH
DOI：
10.3122/jabfm.16.6.494
发表时间：
2003-11-01
期刊：
JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE
影响因子：
--
作者：
Fenton, JJ;Deyo, RA
通讯作者：
Deyo, RA
影响因子：
12.7
作者：
Yarnall, KSH;Pollak, KI;Michener, JL
通讯作者：
Michener, JL